ZYNE Zynerba Pharmaceuticals, Inc.

7.30
+0  (0%)
Previous Close 7.30
Open 7.30
Price To book 1.86
Market Cap 67.15M
Shares 9,199,000
Volume 112,586
Short Ratio 5.08
Av. Daily Volume 201,943

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 to be initiated 2H 2017.
ZYN001
Fibromyalgia
Phase 2 to be initiated 2H 2017.
ZYN001
Peripheral Neuropathic Pain (PNP)
Phase 2 trial initiation announced January 3, 2017. Data are due late 1H 2017.
ZYN002
Fragile X syndrome
Phase 2 initiated September 2016. Data are due July or August 2017.
ZYN002
Osteoarthritis
Phase 2 dosing commenced August 2016. Data are due July or August 2017.
ZYN002
Adult Epilepsy Patients with Refractory Focal Seizures

Latest News

  1. Cannabis Space Continues To Shine As Latest IPO Therapix BioSciences (TRPX) Oversubscribed
  2. Agile Therapeutics (AGRX) Catches Eye: Stock Moves Up 14%
  3. Zynerba Pharmaceuticals to Report Fourth Quarter and Full-Year 2016 Financial and Operating Results on March 27, 2017
  4. Zynerba Pharmaceuticals Announces Completion of Enrollment for ZYN002 in Two Phase 2 Clinical Trials for Epilepsy and Osteoarthritis
  5. ZYNERBA PHARMACEUTICALS, INC. Files SEC form 8-K, Regulation FD Disclosure, Other Events, Financial Statements and Ex
  6. Emerging Cannabis Industry Presents Big Opportunities For Investors
  7. Zynerba Pharmaceuticals to Participate in Upcoming Investor Conferences
  8. Coverage initiated on Zynerba Pharma by Maxim Group
  9. (2/23) This Week’s Earnings Revisions Movers
  10. Zynerba Pharmaceuticals (ZYNE) Shares March Higher, Can It Continue?
  11. Patterson Companies (PDCO) Q3 Earnings: What's in Store?
  12. Medtronic (MDT) Q3 Earnings: Disappointment in the Cards?
  13. Harry Boxer: These four momentum stocks are breaking out
  14. ZYNERBA PHARMACEUTICALS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits
  15. Zynerba Pharmaceuticals Announces Full Exercise of Underwriters' Option to Purchase Additional Shares
  16. Innovative Marijuana-Based Medicines In the Making
  17. ZYNERBA PHARMACEUTICALS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits
  18. Cannabis Drug Company Zynerba Is Gearing Up For A Big Summer
  19. Cannabis Stocks Do Not Trade on Earnings, Instead on Pipeline of Drugs
  20. Developer of cannabinoid patch seeking $50M from stock sale